| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 159.43% | HC Wainwright & Co. | $2 → $3 | Maintains | Neutral |
| 08/14/2023 | 72.95% | HC Wainwright & Co. | $3 → $2 | Maintains | Neutral |
| 05/15/2023 | 159.43% | HC Wainwright & Co. | → $3 | Reiterates | Neutral → Neutral |
| 03/20/2023 | 159.43% | HC Wainwright & Co. | $6 → $3 | Downgrades | Buy → Neutral |
| 02/23/2023 | 418.85% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 11/14/2022 | 418.85% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 08/15/2022 | 678.28% | HC Wainwright & Co. | $12 → $9 | Maintains | Buy |
| 08/12/2022 | 332.38% | Sidoti & Co. | → $5 | Downgrades | Buy → Neutral |
| 05/16/2022 | 937.7% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 11/12/2021 | 1197.13% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 03/29/2021 | — | Maxim Group | Downgrades | Buy → Hold | |
| 03/26/2021 | 1283.6% | HC Wainwright & Co. | $30 → $16 | Maintains | Buy |
| 12/15/2020 | 2494.26% | HC Wainwright & Co. | $29 → $30 | Maintains | Buy |
| 11/17/2020 | 2407.78% | HC Wainwright & Co. | $33 → $29 | Maintains | Buy |
| 08/14/2020 | 2753.68% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/20/2020 | 2494.26% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 05/18/2020 | 2926.63% | HC Wainwright & Co. | $20 → $35 | Reiterates | → Buy |
| 03/03/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 02/24/2020 | 245.9% | HC Wainwright & Co. | $2 → $4 | Maintains | Buy |
| 04/09/2019 | 72.95% | Maxim Group | → $2 | Initiates Coverage On | → Buy |
| 03/11/2019 | 72.95% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
What is the target price for Co-Diagnostics (CODX)?
The latest price target for Co-Diagnostics (NASDAQ: CODX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $3.00 expecting CODX to rise to within 12 months (a possible 159.43% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Co-Diagnostics (CODX)?
The latest analyst rating for Co-Diagnostics (NASDAQ: CODX) was provided by HC Wainwright & Co., and Co-Diagnostics maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Co-Diagnostics (CODX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Co-Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Co-Diagnostics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Co-Diagnostics (CODX) correct?
While ratings are subjective and will change, the latest Co-Diagnostics (CODX) rating was a maintained with a price target of $2.00 to $3.00. The current price Co-Diagnostics (CODX) is trading at is $1.16, which is out of the analyst's predicted range.